DEF: Cigna Group Navigates Dynamic Environment, Reports 27% Revenue Growth in 2024

The Cigna Group reports strong revenue growth and strategic advancements in 2024, while addressing challenges in medical costs and setting future performance targets.

Summary

• The Cigna Group reported a 27% increase in full-year total revenues, reaching $247.1 billion in 2024.
• Shareholders' net income was $3.4 billion, or $12.12 per share, while adjusted income from operations reached $7.7 billion, or $27.33 per share, a 9% increase year-over-year.
• The company returned $8.6 billion to shareholders through dividends and share repurchases.
• Despite strong overall performance, 2024 results were below expectations due to higher-than-anticipated medical costs in the stop loss product within Cigna Healthcare.
• Corrective actions are being taken to address this issue, with margin recapture expected over the next two years.
• For 2025, the company anticipates adjusted income from operations of at least $29.50 per share and approximately $10 billion of operating cash flow.
• The long-term average annual adjusted earnings per share growth target remains 10-14%.
• The sale of the Medicare businesses to Health Care Service Corporation (HCSC) is expected to close in the first quarter of 2025.
• The Cigna Group Foundation will allocate more than $27 million in grants to nonprofit organizations over the next three years, focusing on youth and veteran mental health, and reducing barriers to health equity.

Sentiment

Score: 7

Explanation: The document presents a mix of positive financial results and strategic initiatives, balanced with the acknowledgement of challenges and corrective actions. The overall tone is optimistic but realistic.

Positives

• The Cigna Group grew full-year total revenues by 27% to $247.1 billion in 2024.
• Adjusted income from operations reached $7.7 billion, or $27.33 per share, reflecting a 9% increase in adjusted earnings per share year-over-year.
• The company returned $8.6 billion to shareholders through dividends and share repurchases.
• Evernorth Health Services achieved nearly 50% biosimilar penetration among eligible HUMIRA scripts at year-end 2024.
• Approximately eight million individuals were enrolled in EncircleRx, a solution to manage GLP-1 medication costs.
• More than 6.5 million customers were enrolled in Cigna Pathwell Specialty in 2024.
• The Cigna Group Foundation will allocate more than $27 million in grants to nonprofit organizations over the next three years.
• The company expects adjusted income from operations of at least $29.50 per share in 2025.
• The company grew total customer relationships in 2024 by 11% to approximately 182 million.

Negatives

• 2024 results were below expectations due to higher-than-anticipated medical costs in the stop loss product within Cigna Healthcare.

Risks

• Higher-than-anticipated medical costs in the stop loss product within Cigna Healthcare impacted 2024 results.
• The company recognizes the need to accelerate change for individuals and make their experience of the health care system better.

Future Outlook

The company is confident that it will deliver on its adjusted income from operations outlook of at least $29.50 per share and approximately $10 billion of operating cash flow in 2025, and its long-term average annual adjusted earnings per share growth target remains 10-14%.

Management Comments

• David M. Cordani: 'The mission of The Cigna Group, to improve the health and vitality of those we serve, guided us in navigating a highly dynamic environment in 2024 while we also strengthened our capabilities and grew our business.'
• Starting in 2025, a portion of leaders' compensation will be tied to improving customer and patient satisfaction.

Industry Context

The announcement highlights the company's focus on affordable and innovative healthcare solutions, addressing key industry trends such as the rise of GLP-1 medications, the mental health crisis, and the need for better navigation support for patients.

Comparison to Industry Standards

• The document mentions biosimilar penetration among eligible HUMIRA scripts reaching nearly 50% at year-end 2024, which could be compared to the biosimilar adoption rates of competitors like CVS Health or UnitedHealth Group.
• The document mentions the company's expansion in International Health in the Kingdom of Saudi Arabia, given its global expertise in health insurance and value-based healthcare. This could be compared to the international expansion strategies of competitors like Allianz or Bupa.
• The document mentions the company's focus on growth priorities in Cigna Healthcare and Evernorth, resulting in the announced sale of our Medicare businesses to Health Care Service Corporation (HCSC). This could be compared to the divestiture strategies of competitors like Aetna or Humana.

Related Party Transactions

• A member of Mr. Wiseman's family is an employee of The Cigna Group. The position that employee holds is not an executive officer or enterprise-level strategic role. Target total annual compensation for this position is determined by reference to a range of compensation for similarly situated roles and is approximately $130,000 to $220,000.

Stakeholder Impact

• The company aims to deliver value for customers, patients, and clients through affordable and innovative solutions.
• The company is committed to improving the health and vitality of communities through philanthropic and community engagement initiatives.
• The company prioritizes the health and vitality of its employees through various wellness programs and benefits.

Next Steps

• The transaction of selling the Medicare businesses to Health Care Service Corporation (HCSC) is expected to close in the first quarter of 2025.
• The company will offer a STELARA biosimilar, again for $0, beginning in 2025.
• The 2025 Annual Meeting of Shareholders will be held on April 23, 2025.

Key Dates